Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.7175 USD -4.33% Intraday chart for OpGen, Inc. +37.95% +70.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading MT
Opgen, Inc. Announces Executive Changes CI
Opgen, Inc. Announces Chief Executive Officer Changes CI
Earnings Flash (OPGN) OPGEN Posts Q3 Revenue $699,022 MT
OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
OpGen to Raise $1 Million From Private Placement Amid Talks For 'Potential Strategic' Deal MT
OpGen, Inc. announced that it expects to receive $1 million in funding CI
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected MT
Investors Await Inflation Data, Consumer Sentiment Report as US Futures Trend Higher Friday MT
Top Premarket Gainers MT
North American Morning Briefing : China Angst -2- DJ
HC Wainwright Downgrades OpGen to Neutral From Buy MT
Opgen Exploring Options CI
OpGen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : OpGen, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (OPGN) OPGEN Reports Q2 Revenue $736,136, vs. Street Est of $900,000 MT
Transcript : OpGen, Inc., Q1 2023 Earnings Call, May 15, 2023
Earnings Flash (OPGN) OPGEN Posts Q1 Revenue $0.91M MT
OpGen, Inc. Provides Revenue Guidance for the Year 2023 CI
OpGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
US Stocks Set to Open Lower Amid Earnings Reports, Rising Personal Income MT
OpGen, Fisher Healthcare Sign Non-Exclusive Distribution Agreement for Unyvero A50 Platform MT
Opgen, Inc. Submits De Novo Request to the U.S. FDA for Unyvero Urinary Tract Infection Panel CI
OpGen, Inc. Enters into Non-Exclusive Distribution Agreement with Fisher Healthcare CI
OpGen Files De Novo Market Authorization Request With US FDA for Urinary Tract Infection Panel, Shares Rise Pre-Bell MT
Chart OpGen, Inc.
More charts
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company's product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company's subsidiaries include Curetis GmbH and Ares Genetics GmbH.
More about the company
  1. Stock
  2. Equities
  3. Stock OpGen, Inc. - Nasdaq
  4. News OpGen, Inc.
  5. Alliance Global Downgrades OpGen to Neutral From Buy, Adjusts Price Target to $0.67 From $1.25